BridgeBio gets rights to Novartis' FGFR kinase inhibitor

Novartis AG (NYSE:NVS; SIX:NOVN) granted BridgeBio Pharma LLC (Palo Alto, Calif.) rights to infigratinib (BGJ398), a

Read the full 166 word article

User Sign In